Supreme activity of gramicidin S against resistant, persistent and biofilm cells of staphylococci and enterococci. by Berditsch, M et al.
1Scientific RepoRtS |         (2019) 9:17938  | https://doi.org/10.1038/s41598-019-54212-z
www.nature.com/scientificreports
Supreme activity of gramicidin S 
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Three promising antibacterial peptides were studied with regard to their ability to inhibit the 
growth and kill the cells of clinical strains of Staphylococcus aureus, Enterococcus faecalis and 
Enterococcus faecium. The multifunctional gramicidin S (GS) was the most potent, compared to the 
membranotropic temporin L (TL), being more effective than the innate-defence regulator IDR-1018 
(IDR). These activities, compared across 16 strains as minimal bactericidal and minimal inhibitory 
concentrations (MIC), are independent of bacterial resistance pattern, phenotype variations and/
or biofilm-forming potency. For S. aureus strains, complete killing is accomplished by all peptides at 
5 × Mic. for E. faecalis strains, only GS exhibits a rapid bactericidal effect at 5 × MIC, while TL and 
IDR require higher concentrations. The biofilm-preventing activities of all peptides against the six 
strains with the largest biofilm biomass were compared. GS demonstrates the lowest minimal biofilm 
inhibiting concentrations, whereas TL and IDR are consistently less effective. In mature biofilms, 
only GS completely kills the cells of all studied strains. We compare the physicochemical properties, 
membranolytic activities, model pharmacokinetics and eukaryotic toxicities of the peptides and explain 
the bactericidal, antipersister and antibiofilm activities of GS by its elevated stability, pronounced cell-
penetration ability and effective utilization of multiple modes of antibacterial action.
Inappropriate use of antibiotics in medicine and agriculture has led to the emergence of resistant bacteria world-
wide, endangering the clinical efficacy of conventional antibiotic regiments1. Among Gram-positive pathogens, a 
global pandemic of resistant Staphylococcus aureus and Enterococcus species currently poses the greatest threat1. 
Notably, both bacterial groups are among the major nosocomial opportunistic pathogens (ESKAPE group), for 
which the spread of multidrug-resistant (MDR) strains and high clinical relevance are well recognized2. In par-
ticular, staphylococci are a leading cause of bacteraemia and infective endocarditis as well as osteoarticular, skin/
soft tissue, pleuropulmonary and device-related infections. Many staphylococci have become resistant to prac-
tically all of the commonly available agents. A notorious case is methicillin-resistant S. aureus (MRSA), perhaps 
the most studied example of the kind. Some strains of MRSA possess an additional resistance to aminoglycosides, 
macrolides, tetracyclines, amphenicols, lincosamides, rifampicin, daptomycin, mupirocin and fusidic acid3–7. 
Fortunately, due to the infrequency of horizontal gene transfer from vancomycin-resistant enterococci, only 
rare cases of completely vancomycin-resistant S. aureus (VRSA) isolates have been found8. In medical practice, 
enterococci are known to cause a wide range of clinical infections, from localized urinary tract infections and 
intra-abdominal infections to sepsis and endocarditis9. Enterococci are also a prominent cause of complex endo-
dontic infections, including cases reported to be caused by tetracycline-resistant E. faecalis (TRE)10. Enterococcus 
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faecium and E. faecalis are recognized causes of nosocomial infections and are ranked second (after S. aureus and 
S. epidermidis) as aetiological agents of hospital-associated infections11.
Besides genetic adaptation, bacterial resistance to antibiotics can also have a lifestyle-associated or pheno-
typic nature. This broad and intrinsic multidrug tolerance is often attributed either to the ability of bacterial cells 
to aggregate and adhere to surfaces, forming biofilms, or to the existence of small subpopulations of dormant 
persister cells within bacterial communities12,13. Biofilm-related or persisting infections are mostly chronic and 
require more intense care14. Biofilms are difficult to treat with antibiotics, because sessile cells are embedded 
in an extracellular, self-produced, complex matrix containing the polysaccharide intercellular adhesin (PIA), 
extracellular DNA, as well as various proteins, lipids and amyloid fibrils15. It has been suggested that the biofilm 
matrix can reduce or delay the infiltration of chemicals, including antibiotics, into the biomass16. In addition, 
biofilms represent a dangerous reservoir of persister cells, which can serve as a nidus of re-infection in the human 
body17. Remarkably, switching to the biofilm lifestyle may occur in planktonic bacteria as a response to an expo-
sure to sub-inhibitory concentrations of antibiotics18,19. We have demonstrated that susceptible S. aureus and E. 
faecalis could sustain the exposure to some membrane-active peptides by switching into sessile growth mode20. 
Importantly, pretreatment with sub-lethal concentrations of antibiotics, irrespective of the growth mode, sub-
stantially increases the levels of persister cells – phenotypic “surviving” cells, which do not experience any genetic 
alterations21,22. Among other proposed mechanisms, transcriptome analysis of some isolated persisters suggested 
toxin-antitoxin modules as important controllers of persister formation17,23. The function of several such mod-
ules was shown to be regulated by the bacterial stress alarmon (p)ppGpp24. It is believed that transitioning into 
metabolically dormant persisters allows bacteria to tolerate antibiotics simply due to the multiplicity of inactive 
targets25.
Frequent isolation of slow-growing clinical pathogens from biofilm-associated infections, can be regarded 
as a medical manifestation of bacterial phenotype switching. These isolates are subpopulations described as 
small-colony variants (SCVs), i.e. forming colonies only one-tenth the size of the common phenotype on agar 
plates26. Although SCVs have been described for many genera of bacteria, they have been studied most exten-
sively in staphylococci25,26. The often transient nature of SCVs suggests that they represent a part of the normal life 
cycle27. Interestingly, an increased biofilm-forming capacity has been reported for many SCVs13.
To combat pathogens with acquired resistance, elevated persistence and/or high biofilm-forming capac-
ity, new treatment approaches using a broad spectrum of alternatives have been suggested28. Among them are 
antibodies, probiotics, bacteriophages, immunostimulants, vaccines, and antimicrobial peptides (AMPs). The 
advantages of antimicrobial peptides are their rapid bactericidal action, low target-based resistance, and low 
immunogenicity28. However, due to poor cell selectivity, resulting in highly unwanted host toxicity, and an intrin-
sic lability to proteases, they are generally not used systemically, although in some instances a topical application 
may effectively supplement systemic therapy28,29. The vast majority of antimicrobial peptides are large molecules, 
resulting in significant production costs and poor pharmacokinetic properties30. Therefore, our particular interest 
was in short sequences that can be efficiently made by chemical synthesis or produced by bacterial fermentation 
at competitive costs31. In this study, we aimed to systematically compare the well-known cyclic decapeptide gram-
icidin S (GS: cyclo[fPVOL]2, f = D-phenylalanine, O = Ornithine) of bacterial origin with two other promising 
peptides, temporin L (TL: FVQWFSKFLGRIL-amide) and IDR-1018 (IDR: VRLIVAVRIWRR-amide)29,32–38. The 
naturally occurring linear tridecapeptide TL was originally found in the skin of Rana temporaria35. Its antimi-
crobial activity is more highly expressed towards Gram-positive bacteria than Gram-negative bacteria36. The 
antibiofilm properties of TL have not been studied. The synthetic linear dodecapeptide “innate defense regulator” 
IDR, was derived by substantial modification of the host-defence peptide bactenecin from bovine neutrophils. 
Its specific antibiofilm activity has been intensively studied in the last decade37,38. Herein, we have examined the 
antibacterial activities of the three peptides towards various relevant clinical strains, including MDR S. aureus, E. 
faecalis and E. faecium, stable and transient SCVs of S. aureus, and strains with elevated biofilm-forming capacity.
Results
Characterization of peptides. The peptides were synthesized by standard solid-phase peptide synthesis 
protocols. Chemical synthesis of GS requires an additional step of cyclization in dilute solution, following the 
cleavage of the linear construct from the resin. Hence, despite having the smallest number of amino acids, GS 
synthesis is more demanding than the production of linear TL and IDR. Luckily, GS is readily available by bacte-
rial fermentation. As it undergoes the same purification steps (high-performance liquid chromatography, HPLC) 
as the other two peptides, irrespective of the production route, its biosynthetic production should be preferred. 
Indeed, when we compared the activities of synthetic and biosynthetically produced GS, we observed no differ-
ence between the two. In the following, only biosynthetic GS was used to avoid batch-to-batch uncertainties.
All three peptides are short (less than 13 residues), amphipathic, and hence are active against lipid bilay-
ers. They carry a net cationic charge, thus possessing an electrostatically mediated selectivity towards anionic 
membranes. They are composed of different types of positively charged amino acids, however, (2 non-canonical 
ornithines in GS, 1 Agr & 1 Lys in TL, and 4 Arg in IDR) and vary in charge density, besides the obvious differ-
ences in secondary structures. Figure 1 shows molecular models of their functionally relevant conformations and 
summarizes the predicted physicochemical properties.
The decameric GS has a symmetric cyclic structure that is rather compact. The two linear peptides are larger in 
size, and IDR is the most highly charged, which results in its lowest absolute hydrophobicity and lowest ability to 
aggregate. A principal difference between the three peptides obviously lies in their conformational propensities. 
In contrast to GS, which maintains a largely constant structure independent of the environment, TL and IDR are 
linear peptidylamides and hence possess much higher conformational plasticity39–41. Indeed, TL and IDR are 
unfolded in aqueous solvents, and TL folds into an α-helix only in membrane-mimicking environments, whereas 
IDR in the presence of membrane models can fold either as an α-helix or as a β-turn.
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Compositional differences translate into functional properties, as observed in the physicochemical exper-
iments addressing the peptides´ mechanisms of action (Fig. 2). Determined under reversed-phase chroma-
tography on a standard C18 column, the apparent hydrophobicity in the partially folded state is in the order 
IDR < TL < GS, corroborating the AGGRESCAN values. The ability to perturb supported zwitterionic lipid mon-
olayers as established models42 for bilayers was measured by rapid cyclic voltammetry (RCV) and correlates best 
with the charge densities, with IDR being the weakest monolayer perturbant (IDR«TL < GS). The same outstand-
ing electrostatic-driven binding by IDR was observed in anion-binding studies (Fig. 2B). Here, we compared the 
interactions of the 3 AMPs with various phosphate-containing cellular metabolites (P-metabolites), by measuring 
31P-NMR spectra in equimolar P-metabolite/AMP aqueous solution. Judging by the disappearance of the signals 
(often with visible precipitate formation) and/or modulation of the chemical shifts, we could distinguish two types of 
interaction in the binary mixtures – (i) no binding, and (ii) 31P-NMR-detected interactions. Most P-metabolites - AMP, 
ADP, GDP, phosphoenolpyruvate, a short-chain phosphatidylcholine (1,2-dihexanoyl-sn-glycero-3 phosphocholine) 
and monophosphate - were not influenced by the presence of the peptides, whereas disctinct interactions with 
ATP, GTP, pyrophosphate, butyryl phosphate and ppGpp suggested a molecular basis for an interference of the 
peptides with the energy metabolism in bacterial cells. In all cases, IDR was found to be the strongest in binding, 
followed by TL and GS, which resemble the order in which the charge density decays.
We further compared the model pharmacokinetic parameters of the peptides by measuring their response to 
biomimetic chromatography conditions. As summarized in Fig. 3, the chromatographic hydrophobicity indices 
(CHIs) of the peptides, irrespective of the ionizing conditions, always revealed the same order IDR < TL < GS 
and showed corresponding binding to the C18 stationary phase in reversed-phase HPLC (Fig. 2A). However, the 
CHI values failed to explain the differential binding to immobilized artificial membranes (IAM). In IAM chro-
matography, where the peptides are partitioning into phosphatidylcholine monolayers (the immobilized lipid 
being 1,2-dimyristoyl-sn-glycero-3 phosphocholine), GS showed again the strongest hydrophobic interaction, 
but TL-binding was significantly weaker than IDR. Interestingly, when the peptides were exposed to other spe-
cies of phosphatidylcholines, the rankings of the ability to bind lipids were different. We thus note the obviously 
strong membrane-perturbing abilities of TL shown in the experiments exploiting DOPC (1,2-dioleoyl-sn-glycero 
3-phosphocholine) as a membrane model (see LoD (=limit of detection) values and RCV plots (Figs. 2C, 3A), and 
the apparent inability of all AMPs to bind 1,2-dihexanoyl-sn-glycero-3-phosphocholine in solution (see 31P-NMR 
results). This discrepancy can be resolved if we consider the lasting prevalence of the hydrophobic binding 
Figure 1. Structural and compositional properties of the studied peptides. (A) Molecular models of the active 
conformations highlighting the distribution of hydrophobic (yellow), polar (cyan) and cationic (blue) residues. 
(B) Theoretical properties of the peptides. AGGRESCAN values were calculated according to reference78 
and represent an average of the amino acid aggregation propensities over the sequence; GRAVY values were 
calculated as a sequence average of hydropathy values79. For both calculations, the lysine values were used to 
characterize non-canonical ornithine. The highest absolute values of all parameters are highlighted with a dark 
gray and the lowest with a white background color.
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forces over the initial electrostatics-mediated attraction to be the major determinants of the peptide-membrane 
interactions. Accordingly, TL and GS both could be suggested as immersing deeper into the apolar core of the 
outer bilayer leaflet to reveal their membranolytic action. Interestingly, the ability to bind to acidic proteins - 
water-soluble human serum albumin (HSA, isoelectric point ~4.7) and to α1-acid glycoprotein (AGP, isoelectric 
point ~3.3) must include hydrophobic contributions from the net cationic peptides, as for both parameters the 
most highly charged IDR revealed only intermediate binding values. Nontheless, all three peptides were found to 
be >90% bound when exposed to HSA- or AGP-immobilized chromatography columns. This high nonspecific 
Figure 2. Representative readouts illustrating the experimentally determined differences between the peptides 
in the following. (A) chromatographic behaviour of the peptide mixture in analytical HPLC using a water/
acetonitrile gradient and C18 stationary phase; (B) interactions with soluble phosphate-containing anions 
observed by 31P-NMR spectroscopy using equimolar mixtures of the peptides with P-metabolites, where no 
interaction (e.g., AMP, left) and strong interaction (e.g., GTP, right) could be demonstrated (black spectra show 
controls without peptide; red spectra show the results upon addition of the peptides); (C) ability to disturb 
zwitterionic lipid monolayers by rapid cyclic voltametry (black traces – RCV plots of pure DOPC on the Hg/Pt 
electrodes; red traces – RCV plots in the presence of different peptide concentrations).
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binding should additionally influence the in vivo pharmacodynamics of all three AMPs, making it tremen-
dously difficult to maintain high bolus blood concentrations. On the other hand, systemic toxicity will also decay 
correspondingly.
Additional pharmacologically relevant differences in the action of AMPs were evident in the evaluation of 
eukaryotic toxicity using various assays (Fig. 3B). In vivo, all three peptides were shown to be acutely toxic. Upon 
extracorporeal application in a zebrafish embryotoxicity model, LD50 values (50% lethality dose) in the 4–10 µM 
range were consistently found. Interestingly, neither the order of toxicity (e.g. IDR < TL~GS for 3 h exposure 
LD50, vs. GS < IDR < TL at 5 µM in the haemolysis assay), nor the absolute toxicity levels correlated between the 
two toxicity assays (IDR and GS taken at LD50 concentrations did not show significant haemolysis). This finding 
suggests that in our in vivo experiments, haemolysis was not the major lethality factor, but other toxicity mech-
anisms could and should have contributed. We also noted that the kinetics of in vivo toxicity varied between the 
peptides. TL was the only peptide where LD50 did not change between 1 hour and 3 hours of exposure, whereas 
IDR and GS killed more embryos at longer incubation times. This result corroborates the anticipated proteolytic 
stability of the three AMPs. TL should be the most labile - it contains a canonical trypsin cleavage site (Lys-Phe); 
IDR should be intermediate as a folded bactenecin analogue43; and GS, due to its cyclic nature and the presence 
of non-canonical amino acids, is essentially not susceptible to proteolysis.
Characterization of bacterial strains. Prior to systematically addressing the antibacterial properties of 
the peptides, we characterized the resistance patterns of the available strains. The resistance of clinical isolates to 
conventional antibiotics was determined in the original laboratories, using the VITEK-2 system. Additionally, 
we tested all staphylococci against mupirocin6, and the control strain S. aureus DSM 1104 and its SCV towards 
methicillin, oxacillin (OXA), gentamicin, tetracycline, and streptomycin, using the standard broth microdilu-
tion procedure44. We also verified the MICs of demeclocycline (DMC), vancomycin and gentamicin against the 
control strain E. faecalis DSM 2570, and E. faecalis isolates WW4 and WW6. The results are summarized in 
Supplementary Information (SI), Table S1. The MDR strains, classified as possessing resistance to at least one 
Figure 3. Quantitative comparison of the experimental physicochemical and toxicity properties of the peptides. 
(A) General hydrophobicity (log k C18); binding to immobilized 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
(log k IAM); ability to perturb DOPC bilayer (LoD, log LoD); binding to HSA (binding, log k HSA); binding to 
AGP (binding, log k AGP); and hydrophobicity under acidic, basic and neutral conditions (CHI pH, log DpH). 
(B) In vivo toxicity (LD50) against zebrafish larvae after 1 hour and 3 hours of exposure and human erythrocyte 
haemolysis at different concentrations. The highest absolute values of all parameters are highlighted with dark 
gray and lowest with a white background color.
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agent in three or more antimicrobial categories45, were S. aureus MRSA9, MRSA9 SCV, MRSA538 SCV, all E. 
faecalis TRE, and E. faecium VRE strains.
Next, we analysed all 16 strains for their biofilm-forming abilities in different nutrient media: a Todd-Hewitt 
(TH) broth, a Mueller-Hinton (MH) broth, and a minimal medium (MM); the latter had been applied previously 
for the study of biofilm eradication38. The purpose of this examination was to determine the conditions that pro-
moted growth with the largest biofilm biomass, and to select the most potent biofilm-forming strains for analyz-
ing the antibiofilm activities of the peptides. Our results (Fig. 4) indicate that cultivation in TH broth is uniformly 
the most appropariate condition that consistently enables the growth of robust biofilms for all bacteria. In the first 
24 hours, vigorous biofilm development was observed among S. aureus for DSM 1104 SCV, MRSA538 SCV, and 
MRSA8 SCV, but not for MRSA9 SCV. The latter isolate grew slowly and, in the conditions of a 96-well microtiter 
plate, required at least 48 hours to complete biofilm development (data not shown). The strongest biofilm-forming 
E. faecalis strains were TRE2, WW4, and WW6, among which only TRE2 is an MDR strain (SI Table S1).
We further analysed the stability of the available S. aureus SCVs. Their reversion into the classical large colony 
variants (LCVs) was defined by streaking of the overnight cultures onto TH agar. As shown in SI Fig. S1, the 
appearance of LCVs in the cultures of DSM 1104 SCV and MRSA9 SCV clearly suggests the transient nature of 
both variants. Additionally, DSM 1104 SCV develops distinct agglomerates in the first hours of growth in the 
liquid culture, followed by passage into fully planktonic growth only after 22 hours of cultivation (SI Fig. S2). 
This observation clearly highlights a unique biofilm-forming ability of DSM 1104 SCV even in liquid medium. 
The remaining S. aureus SCVs grew planktonic when in liquid cultures. MRSA8 SCV and MRSA538 SCV both 
appeared to be stable SCV forms, as they did not revert into LCV (data not shown).
We analysed the peculiarities of the biofilm matrix composition in the transient S. aureus SCVs (DSM 1104 
SCV and MRSA9 SCV), their parental variants, and one stable SCV (MRSA8 SCV) by Congo red staining. The 
interaction with Congo red was studied in two different assays: bacteria were grown as biofilms on hydroxyapatite 
discs (HAD), and as colonies on brain heart infusion agar plates (SI Fig. S3). A distinct black colour suggested the 
elevated production of PIA by both phenotypic variants of DSM 1104, but not by any of the tested MRSA strains. 
These data corroborate previously described biofilm phenotypes of the MSSA strains, which are highly enriched 
in PIA46. Interestingly, the ability to synthesize PIA does not provide DSM 1104 variants with adaptive tolerance 
advantages, as planktonic cells remain sensitive to the action of antibiotics (SI Table S1).
Minimum inhibitory and bactericidal concentrations. Next, we analysed the influence of the peptides 
on all bacterial strains by determining the MIC and minimum bactericidal concentration (MBC) values.
Comparison of the three peptides consistently reveals the best overall antimicrobial activity for GS and the 
worst for IDR (Table 1). The MIC values of GS against S. aureus were mostly 4 µg/ml, only for enterococci they 
were seemingly one dilution higher, approximately 8 µg/ml. The same selectivity trend could be suggested for TL. 
Interestingly, the opposite tendency was apparent for IDR, which was overall more active against enterococci. 
Nevertheless, except for the activity against VRE2, IDR showed the highest MIC values, indicating its globally 
Figure 4. Biofilm-forming capacity in three different growth media. (A) S. aureus strains, (B) E. faecalis and E. 
faecium strains. Orange – when being cultured in TH broth, gray – in MH broth, teal – in MM. Dotted red lines 
represent the level of Crystal violet absorption = 0.9.
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lower antimicrobial activity. Although the MIC values of all three peptides were similar for two clinical E. faecium 
strains, GS clearly had the lowest MBC values.
Time- and concentration-dependent killing effect of peptides. To characterize the killing kinet-
ics, we analysed the exposure of 108 CFU/ml (CFU = colony-forming units) planktonic bacteria to supra-MIC 
concentrations and monitored the cell number as a function of time. With all three peptides, when exposed to 
5 × MIC, S. aureus counts dropped to 101 CFU/ml (LoD) in less than one hour (Fig. 5A). However, the same con-
ditions were less effective against the cells of E. faecalis (SI Fig. S5). Whereas GS at 5 × MIC accomplished killing 
within 60 min in all cases, TL showed comparable effectiveness only against DSM 2570 and TRE2 but was not able 
to eliminate WW6. IDR at 5 × MIC (160 µg/ml) was the worst in performance: it killed only E. faecalis TRE2 cells 
and required the full 60 min. The cells of the other two strains, though reduced in numbers, remained viable (SI 
Fig. S5). At 10 × MIC (Fig. 5B), GS (80 µg/ml) and TL (160 µg/ml) were again able to kill all E. faecalis cells within 
20 min. IDR (320 µg/ml) was similarly effective against DSM 2570, exhibited slower killing of TRE2, and could 
not complete its action against WW6 planktonic cells within 60 min of incubation.
In all cases, we observed a monophasic killing process. At sufficiently high concentration, rapid and com-
plete killing by all antimicrobial peptides suggests that they are effective against persister cells. The results of the 
experiments are also consistent with the MIC/MBC evaluations, collectively allowing the peptides to be ranked as 
GS > TL»IDR in terms of effective bactericidal action against planktonic staphylococci and enterococci.
Minimum biofilm inhibitory concentrations. The MBIC90 (MBIC90 = minimal peptide concentration 
at which a bacterial strain develops <10% of the biofilm biomass of the untreated control) values for GS, TL 
and IDR were determined using a two-fold microdilution procedure, exploiting the best biofilm-forming strains 
identified above (Fig. 4). This parameter quantifies the ability of the peptides to prevent biofilm outgrowth. As 
summarized in Fig. 6A, GS was again the most effective.
Biofilms on hydroxyapatite discs: regrowth and scanning electron microscopy. To characterize 
the viability of the biofilm cells, HAD with pregrown biofilms were exposed for 18 hours to supra-MBIC90 con-
centrations of the AMP, and - after washing - were placed into fresh TH broth. This procedure serves to deter-
mine possible planktonic regrowth from the cells that survived the treatment. The mature extended PIA-enriched 
biofilms of DSM 1104 SCV were tolerant not only to TL and IDR, but also to OXA (Fig. 6B), which was effec-
tive against the planktonic cells at 0.25 µg/ml (SI Table S1). At the same time, the complete lack of regrowth of 
these biofilms after exposure to GS reflects the excellent effectiveness for this particular antibiotic (Fig. 6B). The 
presence of GS abolishes regrowth for both antibiotic-susceptible E. faecalis WW6 and MDR E. faecalis TRE2 
biofilms.
The other two peptides were effective only against the weakest biofilm-former MRSA8 SCV. The 
surface-attached biofilms were also examined by scanning electron microscopy (SEM) to identify potential mor-
phologic changes after peptide treatment. Without any peptide the SEM of the PIA-producing DSM 1104 SCV 
biofilms (Fig. 7A) revealed an external layer, which covered the cells and kept them together. This feature did not 
look like a soft gel, but rather resembled a glazed layer, as is often observed for polysaccharides. The PIA in the 
biofilm of DSM 1104 SCV obviously protected the cells from OXA, TL and IDR, but failed against GS action. 
This finding correlates with the reduced binding affinities of GS to proteins and glycoproteins described above 
Strain
MIC [µg/ml] ( = µM) MBC [µg/ml] ( = µM)
GS TL IDR GS TL IDR
S. aureus
DSM 1104 4 (4) 8 (5) 32 (21) 8 (7) 16 (10) 128 (83)
DSM 1104 SCV 4 (4) 8 (5) 64 (42) 8 (7) 16 (10) 128 (83)
MRSA3 4 (4) 8 (5) 64 (42) 16 (14) 32 (20) 128 (83)
MRSA4 4 (4) 8 (5) 32 (21) 16 (14) 32 (20)  > 256
MRSA8 SCV 4 (4) 8 (5) 64 (42) 16 (14) 16 (10) 128 (83)
MRSA9 4 (4) 8 (5) 32 (21) 16 (14) 32 (20) 128 (83)
MRSA9 SCV 4 (4) 8 (5) 64 (42) 16 (14) 32 (20) 128 (83)
MRSA538 SCV 8 (7) 16 (10) 64 (42) 16 (14) 32 (20) 128 (83)
E. faecalis
DSM 2570 8 (7) 16 (10) 32 (21) 8 (7) 16 (10) 64 (42)
WW4 8 (7) 16 (10) 32 (21) 16 (14) 32 (20) 64 (42)
WW6 8 (7) 16 (10) 32 (21) 16 (14) 32 (20) 64 (42)
TRE1 8 (7) 16 (10) 32 (21) 16 (14) 32 (20) 64 (42)
TRE2 16 (16) 16 (10) 32 (21) 16 (14) 32 (20) 128 (83)
TRE4 8 (7) 16 (10) 16 (10) 8 (7) 32 (20) 16 (10)
E. faecium
VRE1 8 (7) 8 (5) 16 (10) 8 (7) 16 (10) 32 (21)
VRE2 8 (7) 8 (5) 8 (5) 8 (7) 16 (10) 32 (21)
Table 1. Minimum Inhibitory and Bactericidal Concentrations of GS, TL and IDR.
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Figure 5. Reduction of the bacterial cell number during peptide treatment. (A) S. aureus strains treated at 
5 × MIC. (B) E. faecalis strains treated at 10 × MIC. Dark gray bars are from the control (no peptide), and cell 
counts are shown for incubation with GS (orange), TL (light gray) and IDR (purple). The LoD was 101 CFU/ml 
(red lines).
Figure 6. Antibiofilm activities of the peptides. (A) Minimum biofilm inhibitory concentrations towards 
the strongest biofilm-building strains of staphylococci and enterococci. The highest absolute values of all 
parameters are highlighted with red and lowest with a green background color. (B) Biofilm regrowth after 
treatment with 400 µg/ml peptides or conventional antibiotics. Control (no peptide) is designated “C”.
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(Fig. 3A). In contrast, the adhesion in the PIA-poor biofilms of MRSA8 SCV was observed to be mediated by 
surface proteins and unidentified fibrils (SI Fig. S6). The absence of PIA could be a prime reason for the high 
susceptibility of surface-grown MRSA8 SCV biofilms to the action of all three peptides.
In S. aureus, after exposure to AMPs, the extracellular matrix appeared significantly reduced, suggesting a 
mechanism for biofilm dispersion (Fig. 7). Notably, GS treatment not only caused the highest degree of matrix 
reduction and the lowest number of remaining cells, but also resulted in profound alterations in the morphology 
of the remaining cells. Their surfaces appeared wrinkled, many cells were swollen, and some were clearly dis-
rupted. Such alterations were less pronounced upon exposure to TL and IDR.
Intact E. faecalis TRE2 biofilms were observed as layers of cells with a diameter of about 1 µm, seemingly 
covered by an unknown cell-associated material (Fig. 7B). After GS treatment, this material also disappeared, as 
could be judged from the perceived cell size reduction to about 0.8–0.9 µm. Single and dividing cells no longer 
appeared to be attached together, indicating a dispersion of the biofilm, as in the case of S. aureus. Here, again, 
TL and IDR exhibited poorer dispersion levels and influenced the remaining matrix to a lesser extent. More 
matrix continued to cover and adjoin the remaining cells, which stayed within distinct slime-enclosed aggregates. 
Many cells in both S. aureus DSM 1104 SCV and E. faecalis TRE2 biofilms, after co-incubation with TL and IDR, 
Figure 7. SEM images of biofilms grown on hydroxyapatite surfaces. (A) Cells of DSM 1104 SCV and (B) 
TRE2 biofilms before (C, control) and after treatment with GS, TL and IDR. The magnification of all images was 
15.000 × .
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appeared healthy, which correlates with the higher MBIC90 values and positive regrowth results of these peptides. 
Notably, none of the peptides was able to eradicate the pregrown biofilms completely from the HAD.
Discussion
Among the three peptides compared here, TL and GS are traditionally regarded as amphipathic membranolytic 
AMPs, whereas IDR was originally highlighted as a specific biofilm-targeting peptide. IDR was credited with the 
unique feature of binding to the intracellular alarmon (p)ppGpp, hence offering a new tool to combat the general 
drug tolerance of biofilms. IDR/alarmon interactions were proposed as a universal biofilm-preventing mecha-
nism in multiple Gram-negative and Gram-positive pathogens38,47. In vivo, however, IDR has also been reported 
to differentially accelerate wound healing in several S. aureus-infected porcine and murine models. Notably, these 
effects were not related to the impact of IDR on bacterial colonization levels and could be explained by a modu-
lation of the host response to bacterial challenge, rather than by any specific antibiofilm activity48. Unfortunately, 
another study failed to confirm the preferential activity of IDR against biofilms of Pseudomnas aeruginosa49. Our 
results further corroborate these later findings, revealing the low potency of IDR in preventing the biofilm growth 
of S. aureus and E. faecalis as well as its inability to eliminate pregrown biofilms of S. aureus DSM 1104 SCV, E. 
faecalis TRE2 and WW6. Moreover, it appears that in a broader context of molecular interactions with anionic 
phosphate-containing metabolites, all three peptides are equally selective in binding. In equimolar mixtures, 
quantitative differences in electrostatic binding may be observed (Fig. 2B), but they can be readily explained by 
the higher net positive charge of IDR (Fig. 1).
Here, in the in vitro settings, we demonstrate GS and TL to be de facto more effective than IDR in antibacte-
rial actions against planktonic staphylococci and enterococci (Table 1), as well as in genuine biofilm-preventing 
(Fig. 6A) and biofilm-eliminating activities (Figs. 6B, 7) against numerous representative strains. Our compar-
ative studies showed that GS, TL and IDR are equally effective against regular and persister cells, but the former 
two peptides are superior in the operative killing of planktonic cells at supra-MIC (Fig. 5). The physico-chemical 
ability of GS and TL to insert more deeply into the hydrophobic lipid bilayer core and cause stronger bilayer 
perturbations (Fig. 2C) readily explains their superiority and low selectivity, similar to that of other known mem-
branotropic molecules39,50–55. Taken together with the surprisingly high eukaryotic toxicity of IDR (Fig. 3B), in 
medical practice the “canonical” antimicrobial membrane-active peptides, such as GS and TL, should be more 
applicable. Herein, despite the easier handling of TL due to its lower hydrophobicity, GS is definitely the more 
preferable choice.
Remarkably, only GS but not TL was effective towards all four studied pregrown biofilms, including the 
well-developed biofilm of S. aureus DSM 1104 SCV, the single-cell layer biofilm of MRSA8 SCV, and the biofilms 
of both selected E. faecalis strains (Fig. 6). According to our results, only GS is able to eradicate biofilms with an 
enhanced PIA-matrix and prevent subsequent regrowth. For such dense three-dimensional biofilms, TL and 
IDR, presumably, will require even higher concentrations or much longer times to be equally successful. Overall, 
the activity towards resistant, persistent and biofilm cells of clinical staphylococci and enterococci were found to 
correlate with the hydrophobicity of the peptides: the most hydrophobic peptide, GS, which possesses only two 
positive charges, showed the best activity in all studies.
Historically, GS was isolated from soil bacilli in the early 1940s and was one of the first peptides applied for 
the treatment of infected burns and wounds32,56. Eventhough the successful use of penicillin at that time led to a 
neglect of GS as an antiinfective topical drug, it is currently still being applied. Today, GS is available in Russia as 
a bactericidal agent against sore throats and mouth ulcers in the form of lozenges and the spray GrammidinTM.
Fortunately, the properties and bactericidal mechanisms of GS have been widely studied in recent decades, 
and interestingly some multiple targets besides the lipid bilayer have been confirmed (Fig. 8). In particular, 
these studies revealed that GS is not only able to disrupt lamellar lipid bilayes by forming pores and osmotically 
bursting the bacterial plasma membrane, but it is also able to directly modulate membrane proteins in various 
ways29,39,50–53,57–61. It was shown, e.g., that GS induces clustering of the membrane proteins MinD and DivIVA, 
which are involved in cell division. Complete detachment of the phospholipid synthase PlsX, peptidoglycan syn-
thesis enzyme MurG, and cytochrome C (but interestingly not of ATP synthase) were observed in the membranes 
of Bacillus subtilis after GS treatment57. Interference with the biosynthesis of phospholipids and peptidoglycan 
could additionally explain the appearance of the mesosome-like and non-membranous intracellular structures 
that we observed earlier in the cell interior of GS-treated S. aureus62.
In addition to this repertoire, we can demonstrate that GS is able to enter the cells of Gram-positive ente-
rococci and staphylococci (SI Fig. S7), acting therefore like a genuine cell-penetrating peptide that enters the 
cell directly through the plasma membrane (i.e. non-endocytotically)63. This intrinsic cell-uptake activity has 
already been explored in eukaryotic cells to specifically target mitochondria with GS derivatives64. In the con-
text of prokaryotic cells, together with the ability to bind certain nucleotides and small phosphorylated mole-
cules29–33, GS thus seems to be capable of effectively inhibiting bacterial stress response and biofilm development 
in a fashion previously attributed to IDR. The periplasmic and intracellular binding of anionic phosphorylated 
metabolites by GS should deplete their levels, and therefore inhibit metabolic activity and possibly even affect 
gene regulation, e.g., due to interference with phosphorylation in signal transduction processes. Notably, GS has 
a very high biostability being cyclic and abundant in non-canonical amino acids. Only one natural non-specific 
intracellular serine protease, subtilisin (isolated from B. subtilis) was shown to be effective in degrading GS65. This 
unique proteolytic stability should effectively prolong any factual activity of GS, e.g. its long-term intracellular 
binding of nucleotides, and should thus compensate for its slightly inferior binding efficiency compared to the 
easily degradable IDR or TL, for which the ability to enter bacterial cells is unknown.
Notably, despite long medicinal use, no resistance to GS has ever been documented. We believe that the 
above-described, multifaceted action of GS strongly impedes the development of acquired resistance. Multiple 
mechanisms of cell killing by GS can also explain its pronounced synergistic effect in combination with 
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polymyxin B (PMB, which is known to disrupt the outer bacterial membrane by binding to lipopolysacharides) 
towards biofilms of P. aeruginosa34. This synergy, observed in vitro, suggests the use of GS-PMB combinations 
to treat infections caused by both S. aureus and P. aeruginosa66,67. As an exemplary case study, we have recently 
demonstrated the high therapeutic potential of GS and its combination with PMB for the topical treatment of 
root canal infections29.
With its very cheap production costs, gramicidin S may be extremely useful in both households and clinics 
as an over-the-counter antibacterial and disinfection agent for the prophylactic treatment of primary surface 
infections. Clinical approval would be timely for numerous applications, e.g. solutions for ear infections, sprays 
for applying to large burned areas, and ointments or gels for the local treatment, e.g., of post-operative scars or 
root canal infections29.
Materials and Methods
Peptide synthesis and purification. GS was produced by fermentation of Aneurinibacillus migulanus 
(DSM 5759; formerly Bacillus brevis) and isolated as previously described68. For control experiments and specifi-
cally to monitor cell uptake, GS and its photoswitchable analogue GS-sw(FP), were also synthesized with standard 
N-Fmoc protocols using peptide synthesizer (Syro II, MultiSynthech) as were TL and IDR. All peptides were 
characterized by MALDI mass spectrometry (Bruker Autoflex III). Peptides were purified to >95% employing 
C18 columns (Vydac) and water-acetonitrile gradients on a Jasco HPLC system equipped with an ultraviolet diode 
array detector.
31P-NMR spectroscopy. Fresh solutions of peptides and P-metabolites in 10% D2O (pH 7.2) were combined 
(1:1 mol:mol with 0.224 mM concentration of each component) directly in 5 mm NMR tubes. Room-temperature 
proton-decoupled single-pulse 31P-NMR spectra (7 µs, delay 2 s) were acquired on a Bruker AVANCE 400 spec-
trometer (31P frequency = 162 MHz) using a Bruker BB-PABBO probe.
Electrochemical measurements. The setup for the electrochemical characterization of peptide interac-
tions with DOPC-coated Pt/Hg electrodes was performed as previously detailed69,70. Current vs. potential RCV 
scans were performed at a scan rate of 40 V/s by cycling the potential from −0.4 to −1.2 V with a 5 min sampling 
time. The capacitance current peak at the most negative potential was used for estimating the limit of detection by 
extrapolating a linear fit of capacitance current peak height vs. peptide concentration (1, 5 and 10 µM).
Biomimetic chromatography. HPLC was performed on an Agilent 1100 system with an ultraviolet diode 
array detector. Lipophilicity was measured using a Phenomenex Gemini NT C18 column (50 × 3 mm), a 0.01 M 
formic acid (pH 2.6) or 50 mM ammonium acetate buffers (pH 7.4 and 10.5) as eluent A, and acetonitrile as eluent 
B. The retention times were standardized and chromatographic hydrophobicity index values were determined 
and converted to a 1-octanol/water log D scale as described previously71. Binding measurements were performed 
using Regis Technologies IAM.PC.DD2 (100 × 4.6 mm), HiChrom Chiralpak-HSA (50 × 3 mm) and HiChrom 
Chiralpak-AGP (50 × 3 mm) columns. As eluent A, 50 mM ammonium acetate (pH 7.4) was used with a 0–90% 
acetonitrile gradient (IAM), or a 0–35% 2-propanol gradient for (HSA and AGP) was employed. Retention times 
were converted to log k and % binding, using calibration routines described in72.
Figure 8. Multiple modes of GS action on a Gram-positive bacterial cell. (1) Destabilization/depolarization/
osmotic bursting of plasma membrane51,52,62; (2) membrane permeabilization for ions and small 
molecules39,50,53,57; (3) inhibition of bacterial respiratory proteins80; (4) delocalization and/or clustering of 
peripheral membrane proteins57,58; (5) complexation with nucleic acids59 and nucleotides29,60; and (6) binding of 
intracellular signalling molecules29,61.
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Haemolysis assay. Haemolytic activity was determined with a serial 2-fold dilution assay. Citrate phos-
phate dextrose-stabilized human erythrocyte suspensions were obtained from Karlsruhe Municipal Hospital. The 
washed 0.25% suspension of erythrocytes were incubated with peptides at 37 °C for 30 min as described earlier33. 
The mixture was pelleted (13 000 rpm, 10 min, 4 °C), and the absorbance of the supernatant was recorded at 
540 nm vs. reaction buffer. The extent of haemolysis was related to the action of 0.1% Triton X-100 (100%).
Acute toxicity in Danio rerio embryos. The experiment design complied with European Legislation for 
the Protection of Animals used for Scientific Purposes (Directive 2010/63/EU), in particular, all experiments 
were planned to be done strictly on larvae below 120 hours post fertilization (hpf), which does not require ethical 
commission approval. Experiments were performed in accordance with the relevant OECD testing guidelines73 
and German animal protection standards. Wild type D. rerio embryos were obtained at the European Zebrafish 
Resource Center (Karlsruhe). Fertilized eggs (6 hpf) were raised in 4 ml of embryonic medium (E3) at 28 °C 
until 72 hpf (6-well plate, 20 eggs/well). Embryos were transferred into flat-bottom glass vials (E3, 1 ml, 15–20 
embryos/vial). Peptides were added as 20 µl aliquots in 10% dimethyl sulfoxide in serial 2-fold dilutions. Toxicity 
was expressed as the concentration at which 50% of the embryos were visually observed to die (measured at 1 and 
3 hours exposure) by identifying the heart beat.
Bacterial strains. Control strains S. aureus DSM 1104 and E. faecalis DSM 2570 were purchased from the 
German Collection of Microorganisms and Cell Cultures. The MRSA strains were obtained from the Centre of 
Medical Microbiology (Karlsruhe Municipal Hospital). The WW4 and WW6 isolates were a kind gift of William 
G. Wade (King’s College London). The isolates of E. faecalis TRE1, TRE2, TRE4 and of E. faecium VRE1, VRE2 
were obtained from Dr. Staber & Kollegen (Heilbronn). The resistance of the clinical isolates to conventional 
antibiotics was determined in the original laboratories using the VITEK 2 System (bioMérieux).
congo red staining. Biofilms grown on HAD and on agar plates were used for Congo red staining. The 
HADs were placed into 24-well microtiter plates and filled with 1 ml of bacterial suspension from an overnight 
culture (final OD550 = 0.2, Todd-Hewitt broth). After incubation (37 °C, 24 hours, no agitation), the discs were 
reintroduced into the wells and exposed to 1 ml of 0.08% aqueous Congo red (Sigma-Aldrich) solution for 
2 hours. The results were documented after aspiration of the staining solutions. Bacterial colonies were grown on 
brain heart infusion agar supplemented with 0.8 mg/ml Congo red but lacking glucose74.
Determination of the minimum inhibitory and bactericidal concentrations. For the determina-
tion of MIC, the standard broth microdilution procedure45 was used with a slight modification29. Since the pep-
tide stock solutions were prepared in 50% ethanol, the first rows of the 96-well microtiter plates were filled with 
50 µl of 2 × concentrated Mueller-Hinton broth to reestablish the normal broth concentration after the addition 
of 50 µl peptide solutions. The MIC was determined as the lowest concentration that inhibited bacterial growth, 
judging from bacterial respiration in three parallels for each antibiotic. After incubation of the plates for 22 hours, 
the redox indicator resazurin (Sigma-Aldrich) was added to the wells (20 µl, 80 µM). The plates were incubated 
another 2 hours at 37 °C and 5% CO2. Respiration was determined as the difference in the absorption at 570 nm to 
600 nm, using a microplate reader FLASHScan 550 (Analytik Jena).
MBC was determined directly after the MIC evaluation. The 10 µl samples of all 8 dilution rows in the micr-
otiter plates were spotted on square Mueller-Hinton agar plates and incubated overnight at 37 °C and 5% CO2. 
The MBC was determined as the concentration at which no bacterial colonies were obtained on the two parallel 
spotted plates.
Time-dependent killing effect of peptides. Killing activity was monitored during 60 min exposure to 
peptides at concentrations of 5 × and 10 × MIC. Stationary cultures were diluted in Mueller-Hinton broth to 
OD550 = 0.2. The cells were incubated in 4 ml culture tubes at 37 °C with agitation at 220 rpm. Aliquots (100 µl) 
were taken at 0, 20, 40 and 60 min and diluted 1:10 in Mueller-Hinton broth. Undiluted and diluted aliquots each 
were each spotted as ten 10 µl spots on the agar plates according to the drop-plate method75. Bacterial growth was 
evaluated by counting colonies on the two parallel spotted plates.
Determination of the biofilm-forming capacity. Three nutrient media were used: Todd-Hewitt broth, 
Mueller-Hinton broth and minimal mineral medium38, containing 62 mM potassium phosphate (pH 7.0), 7 mM 
(NH4)2SO4, 2 mM MgSO4, 10 µM FeSO4, 0.4% glucose and 0.5% casamino acids. The central 6 × 3 wells separated 
by empty columns in 96-well microtiter plates were filled with overnight bacterial suspensions of OD550 = 0.2, 
and incubated at 37 °C and 5% CO2 without agitation for 24 hours. The adherent biofilms were washed, dried, 
fixed in MeOH, and dried again. Staining was carried out according to76 in 100 µl of aqueous 0.1% Crystal violet 
(Sigma-Aldrich) for 20 min. Excess dye was removed with water, and the wells were dried. The dye absorbed by 
biofilms was extracted with absolute ethanol (200 µl /well) and quantified in a microtiter plate reader at 595 nm.
Determination of the minimum biofilm inhibitory concentration. Minimum biofilm inhibitory 
concentrations causing a 90% decrease in biofilm growth (MBIC90) were determined using the microdilution pro-
cedure in the same way as for determining MIC, but the wells were inoculated with bacterial cells from stationary 
cultures with 5 × 107 CFU/ml. In contrast to the determination of MBIC for IDR in38, we used Todd-Hewitt broth 
as a medium. After co-incubation with peptides at 37 °C and 5% CO2 without agitation for 24 hours, the plank-
tonic cells were washed, and Crystal violet staining was applied76.
Biofilms on hydroxyapatite discs: regrowth and scanning electron microscopy. Biofilms were 
grown on standardized hydroxyapatite discs (3D Biotek). The discs were placed in 24-well microtiter plates and 
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inoculated with a cell suspension from the overnight stationary culture, grown in Todd-Hewitt broth and diluted 
to OD550 = 0.2. After 30 hours of growth at 37 °C without agitation, the discs were placed for 18 hours in solutions 
containing 400 µg/ml of peptides, dissolved in 10% dimethyl sulfoxide and 150 mM sodium phosphate buffer (pH 
7.2). For the control experiments and conventional antibiotics, pure sodium phosphate buffer was used. After the 
treatment, discs were washed with sodium phosphate buffer, placed into 1 ml of Todd-Hewitt broth and incubated 
at 37 °C with agitation at 200 rpm for 24 hours. After the regrowth experiment, aliquots of the culture were spotted 
on the agar plates as described above to determine the number of remaining viable cells by the negative regrowth.
The second series of hydroxyapatite discs biofilms after the peptide treatment were washed (1x sodium phos-
phate buffer), fixed in 2% glutaraldehyde (sodium phosphate buffer, 1 hour), washed again (2x H2O) and dried 
under ambient sterile conditions. The samples were sputtered to obtain a 1 nm Pt layer using the high-vacuum 
coating system EM MED020 (Leica Microsystems). The images were obtained with a Supra 55 VP field emission 
scanning electron microscope (Carl Zeiss), with an acceleration voltage of 5 kV, working distances of 3.5–3.8 mm, 
and using an Inlens detector for clear topographic imaging in high vacuum mode, with the chamber pressures of 
about 2 × 10−6 mbar.
Fluorescent staining. The intrinsic fluorescence of the photoswitchable analogue GS-sw(FP), described 
previously77, was used to study GS translocation into the cytoplasm. Approximately 1 ml of an E. faeca-
lis cell suspension (OD550 = 1.0) was co-incubated with 100 µg/ml GS-sw(FP) in order to observe cell uptake. 
Carboxyfluorescein succinimidyl ester (Sigma-Aldrich), which is unable to cross the plasma membrane, was 
applied for comparison to stain only the extracellular layers and outer  membrane leaflet. The bacterial suspension 
for the latter staining was resuspended in fresh 150 mM NaHCO3 buffer (pH 8.3). At this increased pH, the amino 
groups of membrane proteins remain deprotonated and can react with the dye. The dye concentration was 1 µl/ml 
(stock solution 10 mg/ml in dimethyl sulfoxide). Both staining experiments were carried out at 37 °C for 30 min 
without agitation. Fluorescence was observed using a Axioskop 40 light microscope (Carl Zeiss) equipped with an 
“A-Plan” objective (100x/1.25 Ph3), a fluorescence filter (type 09, λex = 450–490 nm, λem = 515 nm), and a digital 
camera (PowerShot G5, Canon). Due to the relatively low fluorescence intensity of GS-sw(FP), the exposure time 
was increased fourfold for the GS analogue compared to the control.
Data availability
The data sets generated and/or analyzed in this study are available from the corresponding author on reasonable 
request.
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